New Data on Connecticut Cannabis Sales
Recreational cannabis was approved in the state in June 2021, sales began at the beginning of 2023, and medical cannabis has been legal since 2012.
In a statement (1) dated July 10, the Connecticut Department of Consumer Protection released data concerning sales of cannabis for recreational and medical purposes as collected through its Seed-to-Sale Tracking System.
In the month of June, recreational cannabis sales totaled $12.5 million (1). When combined with the $11.3 million in sales for medical purposes, the total amount of cannabis sales last month in the state totaled close to $24 million (1). In comparison, recreational sales and medical sales for January 2023 totaled $5.1 million and $8 million respectively (1). The statement did note that medical cannabis patients do not pay taxes on their products (1).
Also included was data on the types of products purchased. “In the first six months of sales, 53 percent of sales were usable cannabis, or flower, while vapes made up 25 percent of sales,” the statement also explained (1) “Edible products represented 10 percent of sales.”
The statement also noted that medical cannabis sales in the state were not required to be tracked prior to January 10, 2023 (1).
References
- Consumer Protection releases June cannabis sales data https://portal.ct.gov/DCP/News-Releases-from-the-Department-of-Consumer-Protection/2023-News-Releases/Consumer-Protection-Releases-June-Cannabis-Sales-Data (accessed Jul 12, 2023).
- Connecticut: Medicinal marijuana legalization measure signed into law https://norml.org/news/2012/06/07/connecticut-medicinal-marijuana-legalization-measure-signed-into-law/ (accessed Jul 12, 2023).
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
